Tower Research Capital LLC (TRC)
Position in COYA — Coya Therapeutics, Inc.
CIK 1533421
NEW YORK, NY
Position in COYA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$4,657
-$974 QoQ
Shares Held
1,182
+19.6% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in COYA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Tower Research Capital LLC (TRC) holds $67,724,931 across 440 Biotechnology names. COYA ranks #329 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
12,112 | $8,844,787 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
13,904 | $6,208,692 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4,378 | $3,382,617 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
9,627 | $3,185,285 | |
| 5 | INSM |
INSMED Inc
|
15,410 | $2,519,843 | |
| 6 | LKFT |
Lakefront Biotherapeutics NV
|
66,536 | $1,996,080 | |
| 7 | MRNA |
Moderna, Inc.
|
33,728 | $1,713,382 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
14,349 | $1,065,556 |
All Filings in COYA
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,657 | 1,182 | Shares | Defined | 2026-05-15 | |
| 2025-09-30 | $5,631 | 988 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $3,645 | 634 | Shares | Defined | 2025-08-15 | |
| 2025-03-31 | $1,843 | 285 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $30,093 | 5,252 | Shares | Other | 2025-02-13 | |
| 2024-09-30 | $3,063 | 475 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $16,283 | 2,687 | Shares | Defined | 2024-08-13 | |
| 2023-12-31 | $24,779 | 3,344 | Shares | Defined | 2024-02-13 | |
| 2023-09-30 | $8,067 | 2,101 | Shares | Defined | 2023-11-14 | |
| No filing history on record for this holder in this stock. | ||||||